MenQuadfi

Nazione: Unione Europea

Lingua: finlandese

Fonte: EMA (European Medicines Agency)

Principio attivo:

Neisseria meningitidis group C polysaccharide conjugated to tetanus toxoid, Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid, Neisseria meningitidis group Y polysaccharide conjugated to tetanus toxoid, Neisseria meningitidis group W-135 polysaccharide conjugated to tetanus toxoid

Commercializzato da:

Sanofi Pasteur

Codice ATC:

J07AH08

INN (Nome Internazionale):

meningococcal group A, C, W-135 and Y conjugate vaccine

Gruppo terapeutico:

rokotteet

Area terapeutica:

Meningiitti, meningokokki

Indicazioni terapeutiche:

MenQuadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y. The use of this vaccine should be in accordance with available official recommendations.

Dettagli prodotto:

Revision: 8

Stato dell'autorizzazione:

valtuutettu

Data dell'autorizzazione:

2020-11-18

Foglio illustrativo

504 GATEWAY TIME-OUT

Scheda tecnica

504 GATEWAY TIME-OUT